Ted Lain, MD, MBA, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, discusses the randomized phase 3 THRIVE-AA1 trial (NCT04518995), which assessed the safety
Dr. Farberg explores the evolving treatment landscape for alopecia areata, with a focus on JAK inhibitors and their role in selectively targeting immune pathways involved
Dr. Mirmirani examines the current treatment landscape for extensive and severe alopecia areata, focusing on longstanding unmet needs and how recent FDA-approved therapies are beginning
Dr. Mostaghimi reviews pivotal data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 clinical trials, which evaluated the safety and efficacy of deuruxolitinib in patients with
